MD and CEO Pankaj Jashwant Shah resigns citing personal reasons

CEO resignedKey managerial personnel resignedManagement Changes View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.0%Reaction day

₹115.80

prior close

—

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.4%-2.4% vs market

Healthcare Service Provider peers, median of 27sector+1.1%-3.1% vs sector

On the reaction day the stock moved 2.4 pts less than Nifty Microcap 250 and 3.1 pts less than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.0+0.4-2.4+1.1-3.1

Next day

-3.9+1.7-5.7+1.3-5.2

-5.8+2.1-7.9-0.2-5.6

-7.7+2.1-9.8-0.2-7.5

-9.5+2.1-11.6+0.8-10.3

-11.3+1.9-13.2+0.6-11.9

-12.3+2.4-14.8+1.4-13.8

15d

-25.3+3.0-28.3+0.6-25.9

-16.2+3.7-20.0-0.1-16.2

+8.0+1.6+6.5-4.3+12.4

+21.5-2.7+24.2-7.6+29.1

UpDownMarket · Nifty Microcap 250Sector · Healthcare Service Provider peers, median of 27Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Aspira Pathlab and Diagnostics Ltd has informed BSE that Mr. Pankaj Jashwant Shah (DIN: 02836324) has resigned as Managing Director and Chief Executive Director due to personal reasons with immediate effect from August 3, 2026. The resignation letter was submitted to the Board and signed by Nikunj Mange, Executive Director, on behalf of the company. No replacement has been announced. Disclosure is filed under SEBI LODR Regulation 30.

Likely market impact

Sudden exit of top leadership with no successor named yet. Watch for clarity on succession and strategic continuity.